Although anti-HER2 (human epidermal growth factor receptor 2) therapy is currently
approved for breast, gastric, and gastroesophageal cancers overexpressing the HER2 …

A novel class of drugs, antibody-drug conjugates (ADCs), are now rapidly emerging as
highly effective treatments for solid tumours. ADCs conjugate conventional …

Protein levels and function are poorly predicted by genomic and transcriptomic analysis of
patient tumours. Therefore, direct study of the functional proteome has the potential to …

We sought to develop criteria for ERBB2-positivity (HER2) in colorectal cancer to ensure
accurate identification of ERBB2-amplified metastatic colorectal cancer patients suitable for …

This study aimed at determining the incidence and clinical implications of HER2 status in
primary colorectal cancer (CRC). HER2 status was investigated in two retrospective cohorts …

Background: Anti-HER2/neu therapy is well-established in breast and gastric carcinoma.
The increased understanding of this pathway led to the identification of new promising drugs …

Tumor targeting is a booming business: The global therapeutic monoclonal antibody market
accounted for more than $78 billion in 2012 and is expanding exponentially. Tumors can be …

Metastatic colorectal cancer (mCRC) carries a poor prognosis with an overall 5-year survival
of 13.1%. Therapies guided by tumor profiling have suggested benefit in advanced cancer …

MicroRNAs (miRNAs) regulate cell proliferation, apoptosis and carcinogenesis by targeting
related mRNAs in different types of cancer. miR-331-3p has been found to regulate the …

The human epidermal growth factor receptor 2 (HER2) is a well-established oncogenic
driver and a successful therapeutic target in several malignancies, such as breast and …